<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00779714</url>
  </required_header>
  <id_info>
    <org_study_id>101.321-13/07</org_study_id>
    <secondary_id>EudraCT Nr. 2008-001686-28</secondary_id>
    <nct_id>NCT00779714</nct_id>
  </id_info>
  <brief_title>Comparative Study of Individualized Sensitivity-Directed Chemotherapy Versus DTIC</brief_title>
  <acronym>ChemoSensMM</acronym>
  <official_title>Prospectively Randomized Phase III Study of an Individualized Sensitivity-Directed Combination Chemotherapy Versus DTIC as First-Line Treatment in Stage IV Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hiege-Stiftung gegen Hautkrebs</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>DCS Innovative Diagnostik Systeme</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Wuerzburg</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase III trial is aimed to investigate the efficacy of an individualized,
      sensitivity-directed combination chemotherapy in comparison to the standard regimen DTIC.

      Two question are aimed to be answered by this study:

        1. Is the individual chemosensitivity index (BICSI) a prognostic / predictive biomarker for
           chemotherapy ?

        2. Is an individualized, sensitivity-directed combination chemotherapy superior to the
           standard regimen DTIC in terms of survival and response ?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Melanoma is a cutaneous neoplasm known for its high aggressiveness, its early dissemination
      of metastases, and its poor prognosis once metastasized. Chemotherapy with dacarbacine (DTIC)
      is widely accepted as the standard treatment in metastatic melanoma, with reported response
      rates of about 10%. This poor outcome is assumed to be due to a high chemoresistance
      intrinsic to melanoma cells. However, other therapeutic options like polychemotherapy,
      biochemotherapy, immunotherapy as well as targeted agents did not yet prove to be superior to
      DTIC in multicenter randomized studies.

      Therefore, chemotherapy still is considered as the main therapeutic option in advanced
      metastatic melanoma, and a number of non-standard chemotherapeutics have been tested in small
      pilot studies to improve treatment efficacy. Even though complete remissions of metastatic
      lesions could only be observed in a few patients, these observations indicate a subgroup of
      patients exhibiting high sensitivity to certain anticancer drugs. An in vitro ATP-based
      chemosensitivity assay has been shown to differentiate between chemosensitive and
      chemoresistant melanoma patients. A phase-II-study testing this assay in 53 metastatic
      melanoma patients followed by a sensitivity-directed individualized chemotherapy
      demonstrated, that the chemosensitivity profile of an individual patient, reflected by the
      best individual chemosensitivity index (BICSI), correlated with therapy outcome in terms of
      therapy response and patient overall survival (Ugurel S: Clin Cancer Res 2006).
      Interestingly, a surprisingly high proportion of about 2/5 of the investigated patient cohort
      were classified as chemosensitive, the remaining 3/5 were classified as chemoresistant.
      Objective response was 36.4% in chemosensitive patients compared to 16.1% in chemoresistant
      patients (p=0.114); progression arrest (CR+PR+SD) was 59.1% versus 22.6% (p=0.01).
      Chemosensitive patients showed an increased overall survival of 14.6 months compared to 7.4
      months in chemoresistant patients (p=0.041).

      These encouraging results prompted the initiation of this randomized phase-III-trial
      investigating an individualized sensitivity-directed combination chemotherapy compared to the
      current standard treatment DTIC, as first-line treatment in metastatic melanoma. The
      therapeutics for chemosensitivity testing and treatment of patients were chosen considering
      the results of the phase-II-trial (paclitaxel+cisplatinum, treosulfan+cytarabine).
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2008</start_date>
  <completion_date type="Anticipated">April 2013</completion_date>
  <primary_completion_date type="Anticipated">October 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-specific overall survival</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>Melanoma</condition>
  <arm_group>
    <arm_group_label>A (individualized combined chemotherapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B (DTIC monochemotherapy)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DTIC (dacarbazine)</intervention_name>
    <description>1000 mg/m2, d1 every 21 days</description>
    <arm_group_label>B (DTIC monochemotherapy)</arm_group_label>
    <other_name>detimedac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>paclitaxel + cisplatin</intervention_name>
    <description>paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days</description>
    <arm_group_label>A (individualized combined chemotherapy)</arm_group_label>
    <other_name>taxomedac + cisplatin medac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treosulfan + cytarabine</intervention_name>
    <description>treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days</description>
    <arm_group_label>A (individualized combined chemotherapy)</arm_group_label>
    <other_name>ovastat + alexan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed melanoma of the skin, mucosa, or unknown primary, diagnosed
             with surgically unresectable distant metastases (stage IV according to AJCC).

          -  At least one measurable target lesion according to RECIST, assessed by CT or MRI
             (tumor assessment by X-ray or ultrasonography only is not allowed).

          -  Access to a biopsy of ~1 cm3 from at least one metastatic lesion for in vitro
             chemosensitivity testing. Cell suspensions from malignant effusions are also eligible.

          -  No prior chemotherapy in stage IV (adjuvant chemotherapy in stage III allowed; one
             prior regimen of immunotherapy or targeted therapy in stage IV allowed).

          -  No evidence of brain/CNS metastases. Former history of brain/CNS metastases, which
             have been treated successfully, and are no longer visible in CT/MRI is allowed.

          -  Last complete tumor assessment (CT or MRI of thorax, abdomen and brain) not older than
             14 days prior to registration, and not older than 5 weeks prior to onset of study
             treatment.

          -  ECOG/WHO performance index of 0 or 1.

          -  Patients must have stopped any kind of previous antineoplastic therapy for at least 2
             weeks prior to registration, and at least 4 weeks prior to treatment onset.

          -  Patients must not have concurrent or recent malignancies except for surgically cured
             carcinoma in-situ of the cervix and basal or squamous cell carcinoma of the skin.
             Patients with previous malignancies, which have been treated with a subsequent
             disease-free interval of at least 5 years, are eligible.

          -  Patient age ≥ 18 years.

          -  Adequate hematological, renal and liver function as defined by the following
             laboratory values performed within 14 days prior to randomisation:

               -  absolute neutrophil count (ANC) ≥ 1.5 x 109/l

               -  platelet count ≥ 100 x 109/l

               -  hemoglobin ≥ 9 g/dl

               -  urea and serum creatinine ≤ 2 times upper normal limit (UNL)

               -  total and direct serum bilirubin ≤ 2 times UNL

               -  GOT or GPT ≤ 2.5 times UNL; ≤ 5 times UNL is allowed in case of liver metastasis

               -  alkaline phosphatase &lt; 2.5 times UNL

          -  Female patients should not be pregnant or nursing. Women of childbearing potential
             should be using a highly effective method of birth control (e.g. implants,
             injectables, combined oral contraceptives, some IUDs, sexual abstinence or
             vasectomised partner). For subjects using a hormonal contraceptive method, information
             regarding the product under evaluation and its potential effect on the contraceptive
             should be addressed.

          -  Male patients should use an effective method of contraception.

          -  Before registration, written informed consent must be given according to GCP
             guidelines and national/local regulations. Patients must be willing and giving
             informed consent to participation in the trial.

        Exclusion Criteria:

          -  All metastatic lesions are surgically resectable.

          -  Prior chemotherapy in stage IV (adjuvant chemotherapy in stage III allowed; one prior
             regimen of immunotherapy or targeted therapy in stage IV allowed).

          -  Primary melanoma of the uvea / choroidea.

          -  Evidence of brain/CNS metastases. Former history of brain/CNS metastases, which have
             been treated successfully, and are no longer visible in CT/MRI is allowed.

          -  ECOG/WHO performance index of 2 or higher

          -  Concurrent or recent malignancies except for surgically cured carcinoma in-situ of the
             cervix and basal or squamous cell carcinoma of the skin. Patients with previous
             malignancies, which have been treated with a subsequent disease-free interval of at
             least 5 years, are eligible.

          -  Any severe or uncontrolled hematological, renal or liver dysfunction as defined by the
             laboratory values given in Inclusion Criteria.

          -  Any clinically uncontrolled infectious disease including HIV positivity or
             AIDS-related illness.

          -  Any female patients who are pregnant or nursing.

          -  Any psychological, familial, sociological or geographical condition potentially
             hampering compliance with the study protocol and follow-up schedule; those conditions
             should be discussed with the patient before registration for the trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Selma Ugurel, Prof. (MD)</last_name>
    <role>Study Chair</role>
    <affiliation>Dept of Dermatology, University of Wuerzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Selma Ugurel, Prof. (MD)</last_name>
    <phone>0049931201</phone>
    <phone_ext>26118</phone_ext>
    <email>Ugurel_S@klinik.uni-wuerzburg.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hans F Merk, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Berlin Charite</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Uwe Trefzer, PD (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44791</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Norbert Brockmeyer, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medizinisches Zentrum Bonn Friedensplatz</name>
      <address>
        <city>Bonn</city>
        <zip>53111</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Uwe Reinhold, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Essen</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Dirk Schadendorf, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Frankfurt</name>
      <address>
        <city>Frankfurt / Main</city>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Roland Kaufmann, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology, Klinikum Frankfurt/Oder</name>
      <address>
        <city>Frankfurt/Oder</city>
        <zip>15236</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Anett Milling, Dr. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30449</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ralf Gutzmer, PD (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, Saarland University</name>
      <address>
        <city>Homburg/Saar</city>
        <zip>66421</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Knuth Rass, Dr. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Jena</name>
      <address>
        <city>Jena</city>
        <zip>07740</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Kaatz, Dr. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Schleswig-Holstein Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Axel Hauschild, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology, Klinikum Ludwishafen</name>
      <address>
        <city>Ludwigshafen</city>
        <zip>67063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Edgar Dippel, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Schleswig-Holstein Campus Luebeck</name>
      <address>
        <city>Luebeck</city>
        <zip>23538</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Patrick Terheyden, Dr. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, Univeristy of Magdeburg</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Martin Leverkus, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Mainz</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carmen Loquai, Dr. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68167</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jessica Hassel, Dr. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Marburg</name>
      <address>
        <city>Marburg</city>
        <zip>35033</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Hertl, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Muenchen</name>
      <address>
        <city>Muenchen</city>
        <zip>80337</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Carola Berking, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Muenster</name>
      <address>
        <city>Muenster</city>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Cord Sunderkoetter, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Medical Oncology, Fachklinik Hornheide</name>
      <address>
        <city>Muenster</city>
        <zip>48157</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Michael Fluck, Dr. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dermatology, Klinikum Dorothea Christiane Erxleben</name>
      <address>
        <city>Quedlinburg</city>
        <zip>06484</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jens Ulrich, PD (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Tuebingen</name>
      <address>
        <city>Tuebingen</city>
        <zip>72086</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Claus Garbe, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dept of Dermatology, University of Wuerzburg</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Selma Ugurel, Prof. (MD)</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.ado-homepage.de</url>
    <description>Homepage of organization (ADO, DeCOG) conducting this trial</description>
  </link>
  <reference>
    <citation>Ugurel S, Schadendorf D, Pföhler C, Neuber K, Thoelke A, Ulrich J, Hauschild A, Spieth K, Kaatz M, Rittgen W, Delorme S, Tilgen W, Reinhold U; Dermatologic Cooperative Oncology Group. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group. Clin Cancer Res. 2006 Sep 15;12(18):5454-63.</citation>
    <PMID>17000680</PMID>
  </reference>
  <reference>
    <citation>Ugurel S, Tilgen W, Reinhold U. Chemosensitivity testing in malignant melanoma. Recent Results Cancer Res. 2003;161:81-92.</citation>
    <PMID>12528801</PMID>
  </reference>
  <reference>
    <citation>Cree IA, Neale MH, Myatt NE, de Takats PG, Hall P, Grant J, Kurbacher CM, Reinhold U, Neuber K, MacKie RM, Chana J, Weaver PC, Khoury GG, Sartori C, Andreotti PE. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma. Anticancer Drugs. 1999 Jun;10(5):437-44.</citation>
    <PMID>10477162</PMID>
  </reference>
  <reference>
    <citation>Andreotti PE, Cree IA, Kurbacher CM, Hartmann DM, Linder D, Harel G, Gleiberman I, Caruso PA, Ricks SH, Untch M, et al. Chemosensitivity testing of human tumors using a microplate adenosine triphosphate luminescence assay: clinical correlation for cisplatin resistance of ovarian carcinoma. Cancer Res. 1995 Nov 15;55(22):5276-82.</citation>
    <PMID>7585588</PMID>
  </reference>
  <verification_date>October 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2008</study_first_submitted>
  <study_first_submitted_qc>October 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2008</study_first_posted>
  <last_update_submitted>October 22, 2008</last_update_submitted>
  <last_update_submitted_qc>October 22, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2008</last_update_posted>
  <responsible_party>
    <name_title>Prof. Dr. med. Selma Ugurel</name_title>
    <organization>Dept of Dermatology, University of Wuerzburg</organization>
  </responsible_party>
  <keyword>metastatic (AJCC stage IV)</keyword>
  <keyword>first-line chemotherapy</keyword>
  <keyword>ex-vivo chemosensitivity profiling</keyword>
  <keyword>evaluation of biomarkers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Cytarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

